Table 3.
Results comparison.
| Outcome | CORRECT^ | CORRELATE | Actual series^^ |
|---|---|---|---|
| Median age, years (range) | 61 (64–67) | 65 (24–93) | 65 (35–85) |
| Male, % | 62% | 61% | 58% |
| ECOG | |||
| 0 | 52% | 41% | 21% |
| 1 | 48% | 46% | 66% |
| ≥2 | NA* | 6% | 12% |
| KRAS | |||
| Wild type | 41% | 37% | 38% |
| Mutated | 54% | 56% | 62% |
| Unknown | 5% | 7% | 0% |
| Liver metastasis | NS | 72% | 87% |
| Peritoneum metastasis | NS | 13% | 31% |
| Prior regimens | |||
| 1–2 | 27% | 30% | 22% |
| 3 | 25% | 30% | 51% |
| ≥4 | 49% | 39% | 27% |
| Response evaluation | |||
| Partial response | 1% | 4% | 0% |
| Stable disease | 40% | 22% | 1% |
| Progression | 59%** | 47% | 81% |
| Not evaluated | 27% | 18% | |
| mTD | 1.7 months | 2.5 months | 2.52 months |
| mPFS | 1.9 months | 2.9 months | 2.40 months |
| mOS | 6.4 months | 7.7 months | 4.76 months |
| Safety | |||
| Dose reduction | 38% | 40% | 29% |
| Inferior starting dose | NA | 43% | 56% |
| Toxicity | |||
| Grade 1–2 | 39% | 45% | 68% |
| Grade 3–4 | 54% | 35% | 15% |
| Fatigue | 47% | 41% | 59% |
| Hand–foot skin reaction | 47% | 26% | 29% |
| Diarrhea | 34% | 19% | 8% |
NA, not applicable; NS, not specified; mTD, median treatment duration; mPFS, median progression-free survival; mOS, median overall survival.
^These data are from the cohort treated with regorafenib, not the entire population.
^^Data may not be the same as those reflected in this study because percentages have been rounded in this table.
*ECOG 2 was an exclusion criterion.
**Separate data not provided.